Speaker 1: Hi, Tracy, Welcome. I'm Valerie Bowling. I'm the executive director
Speaker 1: over at the Conference Forum, and I'm with Tracy Kimball,
Speaker 1: who is the director of DEFARM, and we are delighted
Speaker 1: to bring forward information about a particular section of the
Speaker 1: conference called Pharma from the Trenches. So DEFARM, which stands
Speaker 1: for Disruptive Innovations to Modernize Clinical Trials, is happening September
Speaker 1: sixteenth and seventeenth in Philadelphia at the Loew's Hotel. And
Speaker 1: I'm happy to say that we have the whole hotel
Speaker 1: this year because we have to accommodate I think just
Speaker 1: over now a thousand people. Having said that, we are
Speaker 1: doing a series and like little vignettes on covering different
Speaker 1: aspects of the conference. This is a celebration year of
Speaker 1: bringing innovation. Well, in this case, it's really going to
Speaker 1: be from the trenches, which is the theme of this
Speaker 1: particular podcast. But what is DEFARM about. Really, It's about,
Speaker 1: in its simplest form, how can we disrupt the way
Speaker 1: we do clinical research to make trials more efficient, more accessible,
Speaker 1: more inclusive, less expensive, and ultimately far more patient centric
Speaker 1: and hopefully site centric. Right, So those are the goals
Speaker 1: that DEFARM has when every year has to raise the
Speaker 1: bar to reach those goals. And our job is to
Speaker 1: report on innovation. What are people doing that they're really
Speaker 1: proud of that's been working for them, that they can
Speaker 1: share with industry, and that's that's what we bring forward
Speaker 1: at DEFARM. So if you all remember David Letterman's Top
Speaker 1: ten list, I'm going to ask Tracy and challenge Tracy
Speaker 1: to give us the sixteen sessions really short, like thirty
Speaker 1: seconds or less, on what's happening with Fharma from the Trenches,
Speaker 1: which is always featured on day one, in this case
Speaker 1: September sixteenth, and it features sixteen sessions on representing companies
Speaker 1: all pharma on something they're doing very special that they
Speaker 1: want to share to help people in clinical trial operations.
Speaker 1: So I'm setting up the scene for folks, and Trey
Speaker 1: going to hand it over to you to go through
Speaker 1: the sixteen sessions really really briefly, like what's the company
Speaker 1: and what are they going to deliver our share? So
Speaker 1: we're going to start with number sixteen and go for it.
Speaker 1: And by the way, folks, this is not like with
Speaker 1: David Letterman's Top ten, like the number one is like whatever.
Speaker 1: The most outrageous. This is not that this is just
Speaker 1: sixteen and there's nothing in particular order. It's just we
Speaker 1: have sixteen of them, So go ahead, Tracy, to take
Speaker 1: it away.
Speaker 2: We have Amgen reporting on their custom built AI tool
Speaker 2: to advance clinical trial operations. Mind Men on their use
Speaker 2: of large language models for reader oversight in clinical trials
Speaker 2: for efficiency and quality. Pfizer on an evaluation framework for
Speaker 2: using Genitor AI safety and quality focus, gen Map on
Speaker 2: a homegrown AI tool that accelerates safety surveillance.
Speaker 1: Right, that's our first four.
Speaker 2: We have Roach looking at their process for optimizing protocol
Speaker 2: and ements across the portfolio. Vertex reporting on predictive analytics
Speaker 2: and gen AI solutions in clinical trial operations and update
Speaker 2: to their twenty twenty three presentation. Gilead on the use
Speaker 2: of AI and designing, planning and monitoring the performance of
Speaker 2: clinical trials at scale. Moderna on its framework for end
Speaker 2: to end planning and forecasting really focused on breaking down
Speaker 2: silos and streamlining operations across clinical trial operations.
Speaker 1: Okay, so that's our second four. Okay, eight down, eight
Speaker 1: to go go for it. Buysor on its next generation EDC.
Speaker 2: SLASH CDMs platform that they're co developing with a tool provider,
Speaker 2: Santafie on leveraging EHR data at scale to speed patient recruitment.
Speaker 2: Findser on scaling DCT adoption XUS globally, Daichi Sankyo on
Speaker 2: its homegrown clinical operations dash forward and metrics.
Speaker 1: Okay, so I think we got four more to go.
Speaker 2: Regeneron on its use of AI and surveys and to
Speaker 2: call public and private data for patient insights to use
Speaker 2: those in clinical trial design, Booking your angle time on
Speaker 2: its process for rethinking change management to accelerate innovation adoption
Speaker 2: at sites bias. Then on a novel screening ID mechanisms
Speaker 2: it's home grown to drive patient recruitment. And here on
Speaker 2: its proactive engagement strategies for driving future adoption of digital biomarkers.
Speaker 1: All right, nice, So that's our sixteen sessions for Farmer
Speaker 1: from the Trenches, Tracy, Thanks so much again. Defarm September
Speaker 1: sixteenth and seventeenth in Philadelphia, And to get more information,
Speaker 1: just visit our website and at the conferenceform dot org,
Speaker 1: or you could go right to I think it's defarmconference
Speaker 1: dot com. All right, thank you so much